Welcome to our dedicated page for MNKPF news (Ticker: MNKPF), a resource for investors and traders seeking the latest updates and insights on MNKPF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MNKPF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MNKPF's position in the market.
Mallinckrodt plc (OTCMKTS: MNKPF) has appointed Susan Silbermann to its Board of Directors effective October 5, 2022. This expansion brings the board to nine directors, with eight being independent. Susan, a seasoned global healthcare executive with extensive experience at Pfizer, will provide crucial insights as Mallinckrodt aims to enhance its operations and deliver innovative therapies. Her previous leadership roles include overseeing public health and managing Pfizer's COVID-19 task force, indicating her capability to drive growth and long-term value for shareholders.
Mallinckrodt plc (OTCMKTS: MNKPF) announced the submission of a 510(k) premarket notification application to the FDA for an investigational inhaled nitric oxide delivery system linked to INOmax (nitric oxide) gas. If cleared, this system will enhance product delivery, focusing on clinician needs. Notably, INOmax has over 20 years of established efficacy and safety, treating over 875,000 patients globally. However, the safety and efficacy of the new delivery system remain unverified by the FDA.
Mallinckrodt plc (OTCMKTS: MNKPF) has appointed Lisa French as the new Executive Vice President and Chief Commercial Officer, effective October 1, 2022. With over 30 years of experience in commercial biopharmaceuticals, French will oversee the company's commercialization strategy, succeeding Hugh O'Neill, who left the company on September 16, 2022. CEO Siggi Olafsson expressed confidence in French's ability to enhance Mallinckrodt's branding and market presence.
Mallinckrodt (OTCMKTS: MNKPF) announced the FDA approval of Terlivaz (terlipressin), the first and only treatment for adults with hepatorenal syndrome (HRS) involving rapid kidney function reduction. This significant milestone brings a much-needed therapeutic option for critically ill patients requiring hospitalization. The approval is supported by the Phase 3 CONFIRM trial results, which demonstrated terlipressin's efficacy in improving kidney function and avoiding dialysis. Terlivaz is expected to launch in the U.S. soon, aiming to address a condition affecting 30,000-40,000 Americans annually.
Mallinckrodt plc (OTCMKTS: MNKPF) announced changes to its Executive Committee to enhance leadership and stabilize operations. Bryan Reasons remains CFO, while Henriette Nielsen takes on the new role of EVP and Chief Transformation Officer. Mark Tyndall becomes EVP and Chief Legal Officer, and Jason Goodson is now EVP and Head of Corporate Development. Kassie Harrold stays as Chief Compliance Officer, and Stephen Welch leads Specialty Generics. Hugh O'Neill and Steven Romano will depart in mid-September and December, respectively. The company aims to build a more diverse and experienced leadership team for future growth.
Mallinckrodt plc (OTCMKTS: MNKPF) announced the appointment of Karen Ling to its Board of Directors, effective August 12, 2022, expanding the board to eight directors, seven of whom are independent. Ms. Ling brings over 25 years of experience in human resources within the pharmaceutical industry, having held executive positions at AIG and Allergan. Paul Bisaro, Chairman, expressed confidence that her expertise will enhance corporate culture and drive employee engagement. Ms. Ling aims to help Mallinckrodt positively impact patients and drive shareholder value.
Mallinckrodt plc (MNKPF) reported Q2 2022 results, revealing total net sales of $468.7 million, a 14.2% decline year-over-year. The Specialty Brands segment contributed $305.9 million, down 19.8%, due to competition and COVID-related impacts. A net loss of $257.2 million was recorded compared to $105.8 million in the previous year. Despite challenges, the company highlighted significant liquidity exceeding $550 million and a goal to strengthen its balance sheet. Full-year 2022 guidance projects net sales between $1,875 million and $1,925 million.
Mallinckrodt plc (OTCMKTS: MNKPF) announced the presentation of two scientific posters on hepatorenal syndrome (HRS) at the 2022 International Liver Congress in London. These studies focus on the effects of terlipressin, an investigational treatment for rapid kidney function decline associated with HRS. The research highlights early treatment benefits and explores gender differences in clinical responses. Mallinckrodt aims to enhance understanding of HRS management, crucial for approximately 30,000 to 40,000 Americans annually, with a grim prognosis if untreated.